<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36936936</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1135834</StartPage><MedlinePgn>1135834</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1135834</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1135834</ELocationID><Abstract><AbstractText>The global polio eradication campaign has had remarkable success in reducing wild-type poliovirus infection, largely built upon the live attenuated Sabin oral poliovirus vaccine. Whilst rare, vaccine poliovirus strains may cause infection and subsequently revert to a neurovirulent type, termed vaccine-derived poliovirus (VDPV). Persistent, vaccine derived infection may occur in an immunocompromised host (iVDPV), where it is a recognised complication following receipt of the Sabin vaccine. This has significant implications for the global polio eradication campaign and there is currently no agreed global strategy to manage such patients.Here we describe a case of a 50-year-old man with common variable immune deficiency, persistently infected with a neurovirulent vaccine-derived type 2 poliovirus following vaccination in childhood. iVDPV infection had proven resistant to multiple prior attempts at treatment with human breast milk, ribavirin and oral administration of a normal human pooled immunoglobulin product. His iVDPV infection subsequently resolved after 12 days treatment with remdesivir, an adenosine analogue prodrug that is an inhibitor of viral RNA-dependent RNA polymerase, administered as treatment for a prolonged, moderate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. iVDPV from the patient, isolated prior to treatment, was subsequently demonstrated to be sensitive to remdesivir in vitro. Based on the observations made in this case, and the mechanistic rationale for use with iVDPV, there is strong justification for further clinical studies of remdesivir treatment as a potentially curative intervention in patients with iVDPV infection.</AbstractText><CopyrightInformation>Copyright © 2023 Bermingham, Canning, Wilton, Kidd, Klapsa, Majumdar, Sooriyakumar, Martin and Huissoon.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bermingham</LastName><ForeName>William Hywel</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canning</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Virology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilton</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Laboratory, UK Health Security Agency, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klapsa</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Manasi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sooriyakumar</LastName><ForeName>Kavitha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huissoon</LastName><ForeName>Aarnoud P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="Y">Immunologic Deficiency Syndromes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVID - common variable immunodeficiency disorders</Keyword><Keyword MajorTopicYN="N">immune deficiency associated vaccine derived poliovirus (iVDPV)</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">primary immune deficiencies (PID)</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">vaccine derived poliovirus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36936936</ArticleId><ArticleId IdType="pmc">PMC10022663</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1135834</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polio eradication strategy 2022–2026: Delivering on a promise. Geneva: World Health Organization; (2021).</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis (2014) 210(suppl_1):S283–93. doi: 10.1093/infdis/jiu295</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Diop OM, Humayun A, Shahmahmoodi S, El-Sayed ZA, Triki H, et al. . Update on immunodeficiency-associated vaccine-derived polioviruses - worldwide, July 2018-December 2019. MMWR Morb Mortal Wkly Rep (2020) 69(28):913–7. doi: 10.15585/mmwr.mm6928a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: Impact on the global polio eradication initiative. PloS Pathog (2015) 11(8):e1005114. doi: 10.1371/journal.ppat.1005114</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005114</ArticleId><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>Advisory Committee on Dangerous Pathogens (ACDP) . The approved list of biological agents. Heal Saf Exec (2013), 1–32.</Citation></Reference><Reference><Citation>MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O’Leary P, et al. . Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet (2004) 363(9420):1509–13. doi: 10.1016/S0140-6736(04)16150-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16150-3</ArticleId><ArticleId IdType="pubmed">15135598</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G, Redfern O, Pimentel M, Gerry S, Collins G, Malycha J, et al. . The national early warning score 2 (NEWS2). Clin Med (Northfield Il) (2019) 19(3):260. doi: 10.7861/clinmedicine.19-3-260</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.19-3-260</ArticleId><ArticleId IdType="pmc">PMC6542226</ArticleId><ArticleId IdType="pubmed">31092526</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown L-AK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. . Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol (2022) 149(2):557–61. doi: 10.1016/j.jaci.2021.10.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.10.031</ArticleId><ArticleId IdType="pmc">PMC8585958</ArticleId><ArticleId IdType="pubmed">34780850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetty K, Cheng I, Kaliakatsos M, Gonzalez-Granado LI, Klapsa D, Martin J, et al. . Case report: Novel treatment regimen for enterovirus encephalitis in SCID. Front Immunol (2022) 13. doi: 10.3389/fimmu.2022.930031</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.930031</ArticleId><ArticleId IdType="pmc">PMC9513597</ArticleId><ArticleId IdType="pubmed">36177038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR. A phase 1 study of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of V-7404 in healthy adult volunteers. Antimicrob Agents Chemother (2021) 65(10):e01029–21. doi: 10.1128/AAC.01029-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01029-21</ArticleId><ArticleId IdType="pmc">PMC8448163</ArticleId><ArticleId IdType="pubmed">34370575</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapsa D, Wilton T, Zealand A, Bujaki E, Saxentoff E, Troman C, et al. . Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. The Lancet (2022) 400(10362):1531–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, Irannejad M, Abolhassani H, Shahmahmoodi S, Hamidieh AA, Soleyman-Jahi S, et al. . Clearing vaccine-derived poliovirus infection following hematopoietic stem cell transplantation: A case report and review of literature. J Clin Immunol (2018) 38(5):610–6. doi: 10.1007/s10875-018-0521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-018-0521-z</ArticleId><ArticleId IdType="pubmed">29948575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W, Yao M, Dong Y, Ye C, Wang D, Liu H, et al. . Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition. Front Microbiol (2020) 11:1105. doi: 10.3389/fmicb.2020.01105</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01105</ArticleId><ArticleId IdType="pmc">PMC7304253</ArticleId><ArticleId IdType="pubmed">32595613</ArticleId></ArticleIdList></Reference><Reference><Citation>Comunale BA, Engineer L, Jiang Y, Andrews JC, Liu Q, Ji L, et al. . Poliovirus vaccination induces a humoral immune response that cross reacts with SARS-CoV-2. Front Med (2021) 8:1285. doi: 10.3389/fmed.2021.710010</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.710010</ArticleId><ArticleId IdType="pmc">PMC8369257</ArticleId><ArticleId IdType="pubmed">34414206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>